GlaxoSmithKline Pakistan Limited (PSX:GLAXO)
Pakistan
· Delayed Price · Currency is PKR 356.56
-6.79 (-1.87%)
At close: Apr 28, 2026
GlaxoSmithKline Pakistan Income Statement
Financials in millions PKR. Fiscal year is January - December.
Millions PKR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 65,901 | 61,188 | 49,661 | 41,842 | 36,661 | Upgrade
|
| Revenue Growth (YoY) | 7.70% | 23.21% | 18.69% | 14.13% | 4.48% | Upgrade
|
| Cost of Revenue | 41,618 | 45,910 | 46,245 | 34,505 | 26,787 | Upgrade
|
| Gross Profit | 24,283 | 15,277 | 3,416 | 7,336 | 9,874 | Upgrade
|
| Selling, General & Admin | 7,283 | 6,380 | 6,528 | 5,139 | 3,857 | Upgrade
|
| Other Operating Expenses | 640.12 | -1,355 | -5,077 | -2,871 | -856 | Upgrade
|
| Operating Expenses | 7,924 | 5,026 | 1,451 | 2,268 | 3,001 | Upgrade
|
| Operating Income | 16,360 | 10,252 | 1,965 | 5,068 | 6,873 | Upgrade
|
| Interest Expense | -43.12 | -19.28 | -6.52 | -5.37 | -5.43 | Upgrade
|
| Interest & Investment Income | 518.14 | 538.91 | 277.02 | 829.54 | 374.94 | Upgrade
|
| Currency Exchange Gain (Loss) | -51.16 | -221.11 | 68.24 | -703.51 | -156.49 | Upgrade
|
| Other Non Operating Income (Expenses) | -73.27 | -72.38 | -56.48 | -7.37 | -2.52 | Upgrade
|
| EBT Excluding Unusual Items | 16,710 | 10,478 | 2,247 | 5,182 | 7,084 | Upgrade
|
| Merger & Restructuring Charges | -91.29 | -5.61 | -215.25 | -146.51 | -321.57 | Upgrade
|
| Gain (Loss) on Sale of Assets | 74.07 | 21.88 | 82.76 | 124.62 | 633.9 | Upgrade
|
| Asset Writedown | -9.84 | -18.39 | -6.01 | -54.02 | -15.54 | Upgrade
|
| Other Unusual Items | - | - | 68.56 | - | 43.88 | Upgrade
|
| Pretax Income | 16,683 | 10,476 | 2,177 | 5,106 | 7,424 | Upgrade
|
| Income Tax Expense | 6,658 | 3,940 | 1,643 | 2,643 | 2,070 | Upgrade
|
| Earnings From Continuing Operations | 10,025 | 6,536 | 533.95 | 2,463 | 5,354 | Upgrade
|
| Net Income | 10,025 | 6,536 | 533.95 | 2,463 | 5,354 | Upgrade
|
| Net Income to Common | 10,025 | 6,536 | 533.95 | 2,463 | 5,354 | Upgrade
|
| Net Income Growth | 53.39% | 1124.09% | -78.32% | -54.00% | 58.64% | Upgrade
|
| Shares Outstanding (Basic) | 318 | 318 | 318 | 318 | 318 | Upgrade
|
| Shares Outstanding (Diluted) | 318 | 318 | 318 | 318 | 318 | Upgrade
|
| EPS (Basic) | 31.48 | 20.52 | 1.68 | 7.73 | 16.81 | Upgrade
|
| EPS (Diluted) | 31.48 | 20.52 | 1.68 | 7.73 | 16.81 | Upgrade
|
| EPS Growth | 53.39% | 1124.09% | -78.32% | -54.00% | 58.64% | Upgrade
|
| Free Cash Flow | 6,081 | 2,282 | 234.56 | -4,694 | 3,683 | Upgrade
|
| Free Cash Flow Per Share | 19.09 | 7.17 | 0.74 | -14.74 | 11.57 | Upgrade
|
| Dividend Per Share | 17.000 | 10.000 | - | - | 7.000 | Upgrade
|
| Dividend Growth | 70.00% | - | - | - | 7.69% | Upgrade
|
| Gross Margin | 36.85% | 24.97% | 6.88% | 17.53% | 26.93% | Upgrade
|
| Operating Margin | 24.82% | 16.75% | 3.96% | 12.11% | 18.75% | Upgrade
|
| Profit Margin | 15.21% | 10.68% | 1.07% | 5.89% | 14.61% | Upgrade
|
| Free Cash Flow Margin | 9.23% | 3.73% | 0.47% | -11.22% | 10.05% | Upgrade
|
| EBITDA | 17,687 | 11,344 | 2,881 | 5,910 | 7,634 | Upgrade
|
| EBITDA Margin | 26.84% | 18.54% | 5.80% | 14.12% | 20.82% | Upgrade
|
| D&A For EBITDA | 1,327 | 1,093 | 916.48 | 841.69 | 760.47 | Upgrade
|
| EBIT | 16,360 | 10,252 | 1,965 | 5,068 | 6,873 | Upgrade
|
| EBIT Margin | 24.82% | 16.75% | 3.96% | 12.11% | 18.75% | Upgrade
|
| Effective Tax Rate | 39.91% | 37.61% | 75.48% | 51.76% | 27.88% | Upgrade
|
| Advertising Expenses | 20.45 | 24.37 | 22.89 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.